S&P 500   4,582.55 (+0.61%)
DOW   35,478.11 (+0.17%)
QQQ   392.90 (+0.69%)
AAPL   190.81 (+0.22%)
MSFT   384.76 (+0.54%)
META   340.44 (+0.43%)
GOOGL   137.92 (+0.52%)
AMZN   148.20 (+0.80%)
TSLA   249.92 (+1.30%)
NVDA   483.45 (+1.10%)
NIO   7.23 (+0.28%)
BABA   74.99 (-2.28%)
AMD   123.48 (+1.20%)
T   16.19 (+0.06%)
F   10.82 (+4.34%)
MU   76.90 (+1.02%)
CGC   0.55 (+1.98%)
GE   119.45 (+0.50%)
DIS   92.70 (+0.22%)
AMC   6.97 (+4.03%)
PFE   29.78 (+0.30%)
PYPL   59.13 (+1.13%)
XOM   104.43 (+0.51%)
S&P 500   4,582.55 (+0.61%)
DOW   35,478.11 (+0.17%)
QQQ   392.90 (+0.69%)
AAPL   190.81 (+0.22%)
MSFT   384.76 (+0.54%)
META   340.44 (+0.43%)
GOOGL   137.92 (+0.52%)
AMZN   148.20 (+0.80%)
TSLA   249.92 (+1.30%)
NVDA   483.45 (+1.10%)
NIO   7.23 (+0.28%)
BABA   74.99 (-2.28%)
AMD   123.48 (+1.20%)
T   16.19 (+0.06%)
F   10.82 (+4.34%)
MU   76.90 (+1.02%)
CGC   0.55 (+1.98%)
GE   119.45 (+0.50%)
DIS   92.70 (+0.22%)
AMC   6.97 (+4.03%)
PFE   29.78 (+0.30%)
PYPL   59.13 (+1.13%)
XOM   104.43 (+0.51%)
S&P 500   4,582.55 (+0.61%)
DOW   35,478.11 (+0.17%)
QQQ   392.90 (+0.69%)
AAPL   190.81 (+0.22%)
MSFT   384.76 (+0.54%)
META   340.44 (+0.43%)
GOOGL   137.92 (+0.52%)
AMZN   148.20 (+0.80%)
TSLA   249.92 (+1.30%)
NVDA   483.45 (+1.10%)
NIO   7.23 (+0.28%)
BABA   74.99 (-2.28%)
AMD   123.48 (+1.20%)
T   16.19 (+0.06%)
F   10.82 (+4.34%)
MU   76.90 (+1.02%)
CGC   0.55 (+1.98%)
GE   119.45 (+0.50%)
DIS   92.70 (+0.22%)
AMC   6.97 (+4.03%)
PFE   29.78 (+0.30%)
PYPL   59.13 (+1.13%)
XOM   104.43 (+0.51%)
S&P 500   4,582.55 (+0.61%)
DOW   35,478.11 (+0.17%)
QQQ   392.90 (+0.69%)
AAPL   190.81 (+0.22%)
MSFT   384.76 (+0.54%)
META   340.44 (+0.43%)
GOOGL   137.92 (+0.52%)
AMZN   148.20 (+0.80%)
TSLA   249.92 (+1.30%)
NVDA   483.45 (+1.10%)
NIO   7.23 (+0.28%)
BABA   74.99 (-2.28%)
AMD   123.48 (+1.20%)
T   16.19 (+0.06%)
F   10.82 (+4.34%)
MU   76.90 (+1.02%)
CGC   0.55 (+1.98%)
GE   119.45 (+0.50%)
DIS   92.70 (+0.22%)
AMC   6.97 (+4.03%)
PFE   29.78 (+0.30%)
PYPL   59.13 (+1.13%)
XOM   104.43 (+0.51%)

Aytu BioPharma Stock Price, News & Analysis (NASDAQ:AYTU)

$2.36
-0.16 (-6.35%)
(As of 11/28/2023 ET)
Compare
Today's Range
$2.29
$2.54
50-Day Range
$1.55
$3.33
52-Week Range
$1.38
$4.88
Volume
35,229 shs
Average Volume
50,112 shs
Market Capitalization
$13.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Aytu BioPharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
111.9% Upside
$5.00 Price Target
Short Interest
Healthy
11.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

405th out of 949 stocks

Pharmaceutical Preparations Industry

185th out of 444 stocks


AYTU stock logo

About Aytu BioPharma Stock (NASDAQ:AYTU)

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.

AYTU Stock Price History

AYTU Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Aytu BioPharma earnings: here's what to expect
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Earnings Outlook For Aytu BioPharma
Aytu BioPharma earnings: here's what Wall Street expects
See More Headlines
Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/27/2023
Today
11/29/2023
Next Earnings (Estimated)
2/20/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AYTU
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+111.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-17,050,000.00
Pretax Margin
-24.03%

Debt

Sales & Book Value

Annual Sales
$107.40 million
Cash Flow
$0.93 per share
Book Value
$5.78 per share

Miscellaneous

Free Float
5,326,000
Market Cap
$13.15 million
Optionable
Not Optionable
Beta
-0.86
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joshua R. Disbrow (Age 48)
    Chairman & CEO
    Comp: $708k
  • Mr. Mark K. Oki CPA (Age 54)
    CFO, Secretary & Treasurer
    Comp: $522.84k
  • Mr. Greg Pyszczymuka (Age 44)
    Chief Commercial Officer
    Comp: $525k
  • Ms. Victoria Cordova
    Vice President of People & Culture
  • Mr. Jarrett T. Disbrow Ph.D. (Age 48)
    Chief Business Officer & President of Consumer Health
    Comp: $355k
  • Mr. Russ McMahen
    Senior Vice President of Research & Development
  • Mr. Ryan J. Selhorn CPA (Age 41)
    Executive VP of Finance & Business Optimization














AYTU Stock Analysis - Frequently Asked Questions

Should I buy or sell Aytu BioPharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AYTU shares.
View AYTU analyst ratings
or view top-rated stocks.

What is Aytu BioPharma's stock price target for 2024?

2 brokers have issued 12-month price objectives for Aytu BioPharma's stock. Their AYTU share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 111.9% from the stock's current price.
View analysts price targets for AYTU
or view top-rated stocks among Wall Street analysts.

How have AYTU shares performed in 2023?

Aytu BioPharma's stock was trading at $0.1890 at the start of the year. Since then, AYTU stock has increased by 1,148.7% and is now trading at $2.36.
View the best growth stocks for 2023 here
.

When is Aytu BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our AYTU earnings forecast
.

How were Aytu BioPharma's earnings last quarter?

Aytu BioPharma, Inc. (NASDAQ:AYTU) issued its earnings results on Wednesday, September, 27th. The company reported $0.16 EPS for the quarter. The business earned $30.73 million during the quarter. Aytu BioPharma had a negative trailing twelve-month return on equity of 47.43% and a negative net margin of 24.03%.

When did Aytu BioPharma's stock split?

Aytu BioPharma shares reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aytu BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).

Who are Aytu BioPharma's major shareholders?

Aytu BioPharma's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Greg Pyszczymuka and Joshua R Disbrow.
View institutional ownership trends
.

How do I buy shares of Aytu BioPharma?

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AYTU) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -